Developer docs
API playgroundTry for free, no card

Search company profiles

The AI-Mind project

Full company profile

uuid003e46e

Namestring
The AI-Mind project
Legal namestring
AI-Mind (Artificial Intelligence for Dementia Prevention)
Websiteurl
ai-mind.eu
Company typeenum
Private
Founded yearint
2021
Descriptiontext

The AI-Mind project (legal name: AI-Mind – Artificial Intelligence for Dementia Prevention) is a European research consortium that developed and clinically validated two AI-based digital tools for early dementia risk assessment in people with Mild Cognitive Impairment (MCI). Coordinated by Dr. Ira Haraldsen at Oslo University Hospital, the project ran from March 2021 to February 2026 under Horizon 2020 Grant Agreement No 964220 with an allocated budget of approximately €14 million. It assembled 17 partners across 8 European countries, including leading hospitals (Oslo University Hospital, Helsinki University Hospital, IRCCS San Raffaele Roma), research universities (Complutense University of Madrid, Università Cattolica del Sacro Cuore, Aalto University, University of Oslo), SMEs (BrainSymph AS, Neuroconnect Srl, Lurtis Rules, Pre Diagnostics, accelopment Schweiz AG), patient advocacy (Alzheimer Europe), and industry (Roche for blood biomarker cross-validation).

The technical core of the project is two complementary AI tools. The AI-Mind Connector processes EEG (and related MEG) brain imaging data to evaluate and visualise interactions between brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines Connector outputs with cognitive test results and blood biomarker analysis to produce individual dementia risk predictions with reported accuracy above 95%, using probabilistic machine learning and deep learning approaches. Both tools are integrated into a cloud-based diagnostic support platform administered via the University of Oslo's Services for Sensitive Data (TSD) infrastructure, designed for intuitive use by healthcare professionals, and are positioned for integration into the EBRAINS research infrastructure. The AI models were trained and validated on a multinational clinical dataset of more than 1,000 MCI participants recruited across Norway, Finland, Italy, and Spain.

AI-Mind is not a commercial company and operates no pricing or revenue model. Its sole funding source was the EU Horizon 2020 grant, and it has no paying customers; clinical study participation was free to enrolled patients. Go-to-market is event- and dissemination-driven rather than commercial: the consortium engaged healthcare professionals, policymakers, and patient organisations through conferences (Alzheimer Europe, CTAD, NeurIPS), webinars, multilingual newsletters, policy briefs (including a launch at the European Parliament), and the AI-Mind Share knowledge hub. The project received the first-ever Award for Excellence in Clinical Trials ('Innovative Environment of the Year') from the Norwegian Pharmaceutical Industry Association in early 2026. Operating status is reported as closed following the formal project end in February 2026, with tools transitioning to EBRAINS for downstream research and potential clinical adoption.

Short descriptiontext

The AI-Mind project is a European Horizon 2020 research consortium that developed and clinically validated two AI-based digital tools—the Connector and the Predictor—for early dementia risk assessment in patients with Mild Cognitive Impairment, serving healthcare professionals across Norway, Finland, Italy, and Spain.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI dementia diagnostics, cognitive risk assessment, brain connectivity analysis, clinical decision support, neurodegenerative disease screening
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
NAICS code1 code
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI-based Clinical Decision Support for Neurology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Horizon 2020 Research Funding
TypeManaged Services
Description

The AI-Mind project is a Research and Innovation Action (RIA) funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 964220, with a budget of approximately 14 million euros over five years (2021-2026). The project concluded at the end of February 2026.

ai-mind.eu
2Non-commercial Research Output
TypeLicensing Royalties
Description

The project developed AI tools for clinical use without commercial revenue generation. The tools aim to enable early dementia risk assessment in healthcare systems, with potential for future integration into clinical practice.

ai-mind.eu
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1AI-Mind Connector
Description

An AI-based digital tool that evaluates and visualises interactions between different brain areas using EEG data, identifying early disturbances in the functional brain network as signs of cognitive changes that may develop into dementia.

ai-mind.eu
+2 more records
Core offering1 text field

The AI-Mind project developed two AI-based digital tools — the AI-Mind Connector (analyses EEG data to evaluate functional brain connectivity) and the AI-Mind Predictor (combines brain connectivity, cognitive tests, and blood biomarker data to provide dementia risk prediction with greater than 95% accuracy) — integrated into a cloud-based diagnostic platform intended for use by healthcare professionals to identify people with Mild Cognitive Impairment at elevated risk of developing dementia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Dementia risk prediction accuracy >95%
+2 more records
Product overview1 text field

AI-Mind is a European research project developing two complementary AI-based digital tools integrated into a cloud-based diagnostic support platform. The AI-Mind Connector processes electroencephalography (EEG) brain imaging data to evaluate and visualise interactions between different brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines data from the Connector with cognitive tests and blood biomarkers to provide dementia risk predictions with >95% accuracy for clinical decision-making. Both tools are integrated into a user-friendly cloud platform designed for health professionals to enable earlier and more precise dementia risk assessment for patients with Mild Cognitive Impairment (MCI).

Product and service3 records
1AI-Mind Connector
CategoryAI-based Clinical Decision Support
Description

An AI-based digital tool fed with brain images from electroencephalography (EEG) data that evaluates and visualises interactions between different brain areas, identifying early disturbances in the functional brain network as the first signs of cognitive changes that may develop into dementia. Targeted at healthcare professionals for clinical decision support.

2AI-Mind Predictor
CategoryAI-based Clinical Decision Support
Description

An AI-powered tool that combines data from the AI-Mind Connector, cognitive tests, and blood analysis to provide accurate (>95%) prediction of dementia risk for clinical decision-making for people with Mild Cognitive Impairment. Targeted at healthcare professionals (neurologists, geriatricians, clinical researchers).

3AI-Mind Cloud-Based Diagnostic Platform
CategoryCloud-based Clinical Diagnostic Platform
Description

A cloud-based diagnostic support platform that integrates the AI-Mind Connector and AI-Mind Predictor tools into an easy-to-implement service for health professionals, featuring a user-friendly design and intuitive software. Validated in clinical settings and administered by the University of Oslo Services for Sensitive Data (TSD) for secure data handling.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Lead coordinator of AI-Mind, responsible for overall coordination, communication and management of the project. The Cognitive Health Research group leads clinical trials and the Legal Department leads WP1 on legal and clinical guidelines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

The largest hospital in the Nordic countries with 27,000 employees. Contributes to medical research and innovation strategies strengthening AI and digitalization in patient care and preventive medicine.

3IRCCS San Raffaele Pisana
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Devoted to guarantee excellent care in neurorehabilitation with a cutting-edge facility for translational research. Specializes in brain connectivity and cognitive decline assessment.

ai-mind.eu
4Complutense University of Madrid (UCM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

One of the largest universities in Europe with research resources in neuroscience including the Laboratory of Cognitive and Computational Neuroscience (LNCyC) specializing in MEG, EEG, and DTI-MRI imaging.

ai-mind.eu
5Università Cattolica del Sacro Cuore (UCSC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Participates with Graduate School of Health Economics and Management (ALTEMS) and Memory Clinic handling over 4,000 outpatients yearly with cognitive disorders. Provides health technology assessment expertise.

ai-mind.eu
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Third-largest university in Estonia with School of Digital Technologies conducting research in Digital Learning Ecosystems and Human-Computer Interaction.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Finnish university committed to identifying grand societal challenges with strong technology and AI research capabilities.

8NordSTAR (Nordic Centre for Sustainable and Trustworthy AI Research)
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Centre of research excellence at Oslo Metropolitan University focused on Sustainable and Trustworthy AI with five research groups including Explainable AI and Human factors in AI.

ai-mind.eu
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

R&D-driven company based in Spain and UK committed to creating AI-driven solutions for engineering and science sectors, including early dementia prediction.

10BrainSymph AS
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Medical technology commercialization enterprise founded by neuroscience researchers from Oslo University Hospital, specializing in state-of-the-art EEG with focus on functional brain connectivity.

ai-mind.eu
11Neuroconnect Srl
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Spin-off of Catholic University of the Sacred Heart of Rome, founded in 2018, focusing on brain connectivity and assessment of cognitive decline in MCI, Alzheimer and Stroke patients.

ai-mind.eu
12Alzheimer Europe (AE)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Non-governmental organisation with 39 member national Alzheimer associations in 35 countries. Provides ethical discussions, represents views of people with dementia, and supports communication to public and policymakers.

ai-mind.eu
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-03-01
Description

Swiss SME assisting in EU project management and dissemination/exploitation of project results. ISO 9001 certified with over 25 years experience in Horizon 2020 projects.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Academic hospital in Nijmegen, Netherlands, part of Dutch Federation for university medical centres, focused on innovative and sustainable healthcare development.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Norwegian-based SME specializing in fluid dementia biomarkers, contributing blood analyses on samples from 1,000 study participants for AI model development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Norway's highest-ranked university providing Services for Sensitive Data (TSD) for secure data handling. Administering the AI-Mind platform once deployed.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Global pioneer in pharmaceuticals and diagnostics providing blood biomarker analysis (NeuroToolKit assays including P-tau 181) supporting cross-validation of study samples.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

EU flagship initiative aiming to understand the human brain and its diseases. Partnership supports AI tools development aligned with European Digital Health strategy.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Open research infrastructure gathering data, tools and computing facilities for brain-related research, built with interoperability at the core. AI-Mind tools being integrated into EBRAINS.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-01
Description

Horizon Europe project focusing on creating a decentralized, data protection-compliant research platform for brain health.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Ultra-sensitive immunoassay platform for blood-based biomarkers of neurological disease including Alzheimer's. Comparable as an emerging diagnostic modality for early dementia detection, with a different technology (blood biomarkers vs EEG).

TypeBroad incumbent
Description

Global pharmaceutical and diagnostics leader with established Elecsys blood-based Alzheimer's biomarker assays (pTau181) and a major AI-Mind consortium partner. Comparable as both a blood-biomarker competitor and a potential commercialization partner for AI-Mind.

TypeDirect peer
Description

US-based diagnostics company offering PrecivityAD, a blood-based test for Alzheimer's disease detection. Directly comparable as an early-detection dementia diagnostic and was named as a joint webinar partner with AI-Mind, indicating overlap in target clinical users.

TypeBroad incumbent
Description

Global biotechnology company with leading Alzheimer's therapies (Leqembi) and major interest in companion diagnostics. Comparable as a major incumbent in the Alzheimer's treatment paradigm that AI-Mind's diagnostic could feed into.

TypeDirect peer
Description

Digital cognitive assessment platform using AI/ML on smartphone-based tasks to predict MCI-to-dementia conversion. Comparable in targeting the MCI-to-dementia prediction pathway with an AI/ML diagnostic, but uses digital cognitive markers rather than EEG/MEG.

TypeDirect peer
Description

Digital cognitive assessment platform for concussion and dementia screening, with FDA-cleared products. Comparable in providing clinician-facing cognitive assessment tools targeting early dementia detection.

TypeDirect peer
Description

Belgian AI medical imaging company focused on brain MRI/CT analysis for neurological disorders including multiple sclerosis and dementia. Most directly comparable to AI-Mind in terms of applying AI to brain imaging for neurodegenerative disease diagnostics.

TypeDirect peer
Description

UK neuroscience company providing digital cognitive assessment tools for clinical trials and healthcare. Comparable in providing cognitive testing infrastructure integrated into clinical workflows for early dementia detection.

9Ixico
TypeDirect peer
Description

AI-driven imaging analytics for neurological disorders including Alzheimer's disease, with established clinical trial and pharmaceutical partnerships. Comparable in applying AI to brain imaging for dementia clinical research and diagnostics.

TypeDirect peer
Description

Boston-based digital health company applying AI to cognitive assessment for early detection of dementia and Alzheimer's. Directly comparable in serving the MCI screening use case with a clinician-facing diagnostic platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The AI-Mind project

AI-based Clinical Decision Support for Neurologyai-mind.eu

The AI-Mind project is a European Horizon 2020 research consortium that developed and clinically validated two AI-based digital tools—the Connector and the Predictor—for early dementia risk assessment in patients with Mild Cognitive Impairment, serving healthcare professionals across Norway, Finland, Italy, and Spain.

What The AI-Mind project does

The AI-Mind project (legal name: AI-Mind – Artificial Intelligence for Dementia Prevention) is a European research consortium that developed and clinically validated two AI-based digital tools for early dementia risk assessment in people with Mild Cognitive Impairment (MCI). Coordinated by Dr. Ira Haraldsen at Oslo University Hospital, the project ran from March 2021 to February 2026 under Horizon 2020 Grant Agreement No 964220 with an allocated budget of approximately €14 million. It assembled 17 partners across 8 European countries, including leading hospitals (Oslo University Hospital, Helsinki University Hospital, IRCCS San Raffaele Roma), research universities (Complutense University of Madrid, Università Cattolica del Sacro Cuore, Aalto University, University of Oslo), SMEs (BrainSymph AS, Neuroconnect Srl, Lurtis Rules, Pre Diagnostics, accelopment Schweiz AG), patient advocacy (Alzheimer Europe), and industry (Roche for blood biomarker cross-validation).

The technical core of the project is two complementary AI tools. The AI-Mind Connector processes EEG (and related MEG) brain imaging data to evaluate and visualise interactions between brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines Connector outputs with cognitive test results and blood biomarker analysis to produce individual dementia risk predictions with reported accuracy above 95%, using probabilistic machine learning and deep learning approaches. Both tools are integrated into a cloud-based diagnostic support platform administered via the University of Oslo's Services for Sensitive Data (TSD) infrastructure, designed for intuitive use by healthcare professionals, and are positioned for integration into the EBRAINS research infrastructure. The AI models were trained and validated on a multinational clinical dataset of more than 1,000 MCI participants recruited across Norway, Finland, Italy, and Spain.

AI-Mind is not a commercial company and operates no pricing or revenue model. Its sole funding source was the EU Horizon 2020 grant, and it has no paying customers; clinical study participation was free to enrolled patients. Go-to-market is event- and dissemination-driven rather than commercial: the consortium engaged healthcare professionals, policymakers, and patient organisations through conferences (Alzheimer Europe, CTAD, NeurIPS), webinars, multilingual newsletters, policy briefs (including a launch at the European Parliament), and the AI-Mind Share knowledge hub. The project received the first-ever Award for Excellence in Clinical Trials ('Innovative Environment of the Year') from the Norwegian Pharmaceutical Industry Association in early 2026. Operating status is reported as closed following the formal project end in February 2026, with tools transitioning to EBRAINS for downstream research and potential clinical adoption.

The AI-Mind project firmographics

Firmographics
Name
The AI-Mind project
Legal name
AI-Mind (Artificial Intelligence for Dementia Prevention)
Website
https://ai-mind.eu
Company type
Private
Founded year
2021
Operating status
Closed
Headcount range
1–10 employees
Short description
The AI-Mind project is a European Horizon 2020 research consortium that developed and clinically validated two AI-based digital tools—the Connector and the Predictor—for early dementia risk assessment in patients with Mild Cognitive Impairment, serving healthcare professionals across Norway, Finland, Italy, and Spain.
Ownership category
akta.pro rank

The AI-Mind project industry classification

Industry
Product category
AI-based Clinical Decision Support for Neurology
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise

Keywords

  • AI dementia diagnostics
  • Cognitive risk assessment
  • Brain connectivity analysis
  • Clinical decision support
  • Neurodegenerative disease screening

Where The AI-Mind project is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices5 records

Markets served

The AI-Mind project business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Horizon 2020 Research Funding: The AI-Mind project is a Research and Innovation Action (RIA) funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 964220, with a budget of approximately 14 million euros over five years (2021-2026). The project concluded at the end of February 2026.
  2. Non-commercial Research Output: The project developed AI tools for clinical use without commercial revenue generation. The tools aim to enable early dementia risk assessment in healthcare systems, with potential for future integration into clinical practice.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

The AI-Mind project product offering

Product offering

Core offering

The AI-Mind project developed two AI-based digital tools — the AI-Mind Connector (analyses EEG data to evaluate functional brain connectivity) and the AI-Mind Predictor (combines brain connectivity, cognitive tests, and blood biomarker data to provide dementia risk prediction with greater than 95% accuracy) — integrated into a cloud-based diagnostic platform intended for use by healthcare professionals to identify people with Mild Cognitive Impairment at elevated risk of developing dementia.

Product overview

AI-Mind is a European research project developing two complementary AI-based digital tools integrated into a cloud-based diagnostic support platform. The AI-Mind Connector processes electroencephalography (EEG) brain imaging data to evaluate and visualise interactions between different brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines data from the Connector with cognitive tests and blood biomarkers to provide dementia risk predictions with >95% accuracy for clinical decision-making. Both tools are integrated into a user-friendly cloud platform designed for health professionals to enable earlier and more precise dementia risk assessment for patients with Mild Cognitive Impairment (MCI).

Differentiator

Problem solved

Functional benefit

Brands

  • AI-Mind Connector: An AI-based digital tool that evaluates and visualises interactions between different brain areas using EEG data, identifying early disturbances in the functional brain network as signs of cognitive changes that may develop into dementia.
  • AI-Mind Predictor
  • AI-Mind Share

Products and services

  • AI-Mind Connector An AI-based digital tool fed with brain images from electroencephalography (EEG) data that evaluates and visualises interactions between different brain areas, identifying early disturbances in the functional brain network as the first signs of cognitive changes that may develop into dementia. Targeted at healthcare professionals for clinical decision support.
  • AI-Mind Predictor An AI-powered tool that combines data from the AI-Mind Connector, cognitive tests, and blood analysis to provide accurate (>95%) prediction of dementia risk for clinical decision-making for people with Mild Cognitive Impairment. Targeted at healthcare professionals (neurologists, geriatricians, clinical researchers).
  • AI-Mind Cloud-Based Diagnostic Platform A cloud-based diagnostic support platform that integrates the AI-Mind Connector and AI-Mind Predictor tools into an easy-to-implement service for health professionals, featuring a user-friendly design and intuitive software. Validated in clinical settings and administered by the University of Oslo Services for Sensitive Data (TSD) for secure data handling.

Quantifiable outcome

  • Dementia risk prediction accuracy >95%
  • +2 more outcomes

Companies that use The AI-Mind project

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

The AI-Mind project technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

The AI-Mind project partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core and supporting.

  • Oslo University Hospital (OUS)coreStrategic or Co-development Partner · 1 March 2021Lead coordinator of AI-Mind, responsible for overall coordination, communication and management of the project. The Cognitive Health Research group leads clinical trials and the Legal Department leads WP1 on legal and clinical guidelines.
  • Helsinki University Hospital (HUS)coreStrategic or Co-development Partner · 1 March 2021The largest hospital in the Nordic countries with 27,000 employees. Contributes to medical research and innovation strategies strengthening AI and digitalization in patient care and preventive medicine.
  • IRCCS San Raffaele PisanacoreStrategic or Co-development Partner · 1 March 2021Devoted to guarantee excellent care in neurorehabilitation with a cutting-edge facility for translational research. Specializes in brain connectivity and cognitive decline assessment.
  • Complutense University of Madrid (UCM)coreStrategic or Co-development Partner · 1 March 2021One of the largest universities in Europe with research resources in neuroscience including the Laboratory of Cognitive and Computational Neuroscience (LNCyC) specializing in MEG, EEG, and DTI-MRI imaging.
  • Università Cattolica del Sacro Cuore (UCSC)coreStrategic or Co-development Partner · 1 March 2021Participates with Graduate School of Health Economics and Management (ALTEMS) and Memory Clinic handling over 4,000 outpatients yearly with cognitive disorders. Provides health technology assessment expertise.
  • Tallinn University (TLU)supportingTechnology or Integration · 1 March 2021Third-largest university in Estonia with School of Digital Technologies conducting research in Digital Learning Ecosystems and Human-Computer Interaction.
  • Aalto UniversitysupportingTechnology or Integration · 1 March 2021Finnish university committed to identifying grand societal challenges with strong technology and AI research capabilities.
  • NordSTAR (Nordic Centre for Sustainable and Trustworthy AI Research)supportingTechnology or Integration · 1 March 2021Centre of research excellence at Oslo Metropolitan University focused on Sustainable and Trustworthy AI with five research groups including Explainable AI and Human factors in AI.
  • Lurtis Rules S.L.supportingTechnology or Integration · 1 March 2021R&D-driven company based in Spain and UK committed to creating AI-driven solutions for engineering and science sectors, including early dementia prediction.
  • BrainSymph ASsupportingTechnology or Integration · 1 March 2021Medical technology commercialization enterprise founded by neuroscience researchers from Oslo University Hospital, specializing in state-of-the-art EEG with focus on functional brain connectivity.
  • Neuroconnect SrlsupportingTechnology or Integration · 1 March 2021Spin-off of Catholic University of the Sacred Heart of Rome, founded in 2018, focusing on brain connectivity and assessment of cognitive decline in MCI, Alzheimer and Stroke patients.
  • Alzheimer Europe (AE)coreStrategic or Co-development Partner · 1 March 2021Non-governmental organisation with 39 member national Alzheimer associations in 35 countries. Provides ethical discussions, represents views of people with dementia, and supports communication to public and policymakers.
  • accelopment Schweiz AGcoreImplementation/ SI/ Consulting Partner · 1 March 2021Swiss SME assisting in EU project management and dissemination/exploitation of project results. ISO 9001 certified with over 25 years experience in Horizon 2020 projects.
  • Radboud University Medical Center (RUMC)supportingStrategic or Co-development Partner · 1 March 2021Academic hospital in Nijmegen, Netherlands, part of Dutch Federation for university medical centres, focused on innovative and sustainable healthcare development.
  • Pre Diagnostics (PREDX)supportingTechnology or Integration · 1 March 2021Norwegian-based SME specializing in fluid dementia biomarkers, contributing blood analyses on samples from 1,000 study participants for AI model development.
  • University of Oslo (UiO)coreTechnology or Integration · 1 March 2021Norway's highest-ranked university providing Services for Sensitive Data (TSD) for secure data handling. Administering the AI-Mind platform once deployed.
  • RochecoreStrategic or Co-development Partner · 1 March 2021Global pioneer in pharmaceuticals and diagnostics providing blood biomarker analysis (NeuroToolKit assays including P-tau 181) supporting cross-validation of study samples.
  • Human Brain ProjectsupportingStrategic or Co-development Partner · 1 March 2021EU flagship initiative aiming to understand the human brain and its diseases. Partnership supports AI tools development aligned with European Digital Health strategy.
  • EBRAINSsupportingTechnology or Integration · 1 March 2021Open research infrastructure gathering data, tools and computing facilities for brain-related research, built with interoperability at the core. AI-Mind tools being integrated into EBRAINS.
  • HEALTH DATA CLOUDsupportingTechnology or Integration · 1 March 2021Horizon Europe project focusing on creating a decentralized, data protection-compliant research platform for brain health.

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

The AI-Mind project competitors and assessment

Company assessment

Emerging players

  • Quanterix: Ultra-sensitive immunoassay platform for blood-based biomarkers of neurological disease including Alzheimer's. Comparable as an emerging diagnostic modality for early dementia detection, with a different technology (blood biomarkers vs EEG).

Broad incumbents

  • Roche: Global pharmaceutical and diagnostics leader with established Elecsys blood-based Alzheimer's biomarker assays (pTau181) and a major AI-Mind consortium partner. Comparable as both a blood-biomarker competitor and a potential commercialization partner for AI-Mind.
  • Biogen: Global biotechnology company with leading Alzheimer's therapies (Leqembi) and major interest in companion diagnostics. Comparable as a major incumbent in the Alzheimer's treatment paradigm that AI-Mind's diagnostic could feed into.

Direct peers

  • C2N Diagnostics: US-based diagnostics company offering PrecivityAD, a blood-based test for Alzheimer's disease detection. Directly comparable as an early-detection dementia diagnostic and was named as a joint webinar partner with AI-Mind, indicating overlap in target clinical users.
  • Altoida: Digital cognitive assessment platform using AI/ML on smartphone-based tasks to predict MCI-to-dementia conversion. Comparable in targeting the MCI-to-dementia prediction pathway with an AI/ML diagnostic, but uses digital cognitive markers rather than EEG/MEG.
  • BrainCheck: Digital cognitive assessment platform for concussion and dementia screening, with FDA-cleared products. Comparable in providing clinician-facing cognitive assessment tools targeting early dementia detection.
  • Icometrix: Belgian AI medical imaging company focused on brain MRI/CT analysis for neurological disorders including multiple sclerosis and dementia. Most directly comparable to AI-Mind in terms of applying AI to brain imaging for neurodegenerative disease diagnostics.
  • Cambridge Cognition: UK neuroscience company providing digital cognitive assessment tools for clinical trials and healthcare. Comparable in providing cognitive testing infrastructure integrated into clinical workflows for early dementia detection.
  • Ixico: AI-driven imaging analytics for neurological disorders including Alzheimer's disease, with established clinical trial and pharmaceutical partnerships. Comparable in applying AI to brain imaging for dementia clinical research and diagnostics.
  • Linus Health: Boston-based digital health company applying AI to cognitive assessment for early detection of dementia and Alzheimer's. Directly comparable in serving the MCI screening use case with a clinician-facing diagnostic platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

The AI-Mind project social profiles

Digital presence

The AI-Mind project compliance and trust

Trust signal

Compliance1 record

The AI-Mind project financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The AI-Mind project leadership team

Management profile

Number of profiles

The AI-Mind project funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The AI-Mind project M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The AI-Mind project

What does The AI-Mind project do?

The AI-Mind project developed two AI-based digital tools — the AI-Mind Connector (analyses EEG data to evaluate functional brain connectivity) and the AI-Mind Predictor (combines brain connectivity, cognitive tests, and blood biomarker data to provide dementia risk prediction with greater than 95% accuracy) — integrated into a cloud-based diagnostic platform intended for use by healthcare professionals to identify people with Mild Cognitive Impairment at elevated risk of developing dementia.

Is The AI-Mind project a public or private company?

The AI-Mind project is a private company. It is classified as unknown and is currently closed.

When was The AI-Mind project founded?

The AI-Mind project was founded in 2021. It employs 1 to 10 people.

Where is The AI-Mind project based?

The AI-Mind project is headquartered in Oslo, Norway, in the Europe region.

How does The AI-Mind project make money?

Two revenue lines are on record. Horizon 2020 Research Funding is the primary driver. The others are non-commercial Research Output.

Who are The AI-Mind project's main competitors?

Quanterix is listed as an emerging player. Broad incumbents are Roche and Biogen. Direct peers are C2N Diagnostics, Altoida, BrainCheck, Icometrix, Cambridge Cognition, Ixico and Linus Health.

Does The AI-Mind project have an API?

No public API is recorded for The AI-Mind project.

What industry is The AI-Mind project in?

The AI-Mind project's product category is AI-based Clinical Decision Support for Neurology. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 5182 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales